Yarrow Bioscience stock: Cash runway reaches into 2030

Published on 11/13/2026 at 01:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Yarrow Bioscience stock is in focus after third-quarter results and a clinical update. The company expects cash to fund operations into 2030.

Yarrow advances its clinical program

Yarrow is enrolling patients in the Phase 2a portion of its DIRECTION-GD study for Graves' disease and thyroid eye disease.
Management expects Phase 2a topline results and partner data in the second half of 2027.
The September offering and cash position extend the company's expected funding runway into 2030.

Yarrow Bioscience stock, YARW, third-quarter results, YB-101, Graves' disease, thyroid eye disease, Illustration mit AI erstellt.

Yarrow Bioscience reported third-quarter 2026 results on Thursday, November 12, alongside an update on its lead program for Graves' disease and thyroid eye disease. The Business Wire release carried by StockTitan said enrollment is continuing in the Phase 2a portion of the DIRECTION-GD trial.

Trial milestones remain ahead

The study is evaluating YB-101, an investigational anti-thyroid stimulating hormone receptor antibody, in patients with Graves' disease with or without thyroid eye disease. Yarrow expects topline Phase 2a results in the second half of 2027, while the Phase 2b portion is expected to begin enrolling in the first half of 2028.

Yarrow also said its licensing partner Changchun GeneScience Pharmaceutical is advancing YB-101, known as GenSci098 in Greater China. Data from GeneScience's Phase 1 multiple ascending dose study in thyroid eye disease are also expected in the second half of 2027.

Cash runway supports development

Cash and cash equivalents stood at 268.9 million dollars on September 30, 2026. Yarrow said the balance, including proceeds from its September offering, should fund operations into 2030 and support completion of DIRECTION-GD as well as preparation for a further thyroid eye disease study.

The company raised approximately 172.5 million dollars in gross proceeds through an underwritten offering of 6,634,615 shares in September. Third-quarter research and development expenses were 5.3 million dollars, general and administrative expenses were 5.5 million dollars, and net loss was 9.7 million dollars.

Early-stage position in a competitive field

Yarrow Bioscience is a United States clinical-stage biotechnology company developing YB-101 for autoimmune thyroid diseases, with a focus on Graves' disease and thyroid eye disease. The program is designed to block the interaction between disease-driving autoantibodies and the thyroid stimulating hormone receptor. Yarrow is earlier in development than established thyroid eye disease therapies from Amgen and Roche, while Viridian Therapeutics is also advancing an alternative treatment approach.